GlucoTrack (GCTK)
NASDAQ:GCTK
Want to see GCTK full AI Analyst Report?
GCTK Stock Chart & Stats
$1.93
-$0.03(-1.53%)
At close: 4:00 PM EST
$1.93
-$0.03(-1.53%)
Day’s Range― - ―
52-Week Range$0.62 - $15.90
Previous Close$0.14
Volume19.82K
Average Volume (3M)2.54M
Market Cap
$1.56M
Enterprise Value-$6.90M
Total Cash (Recent Filing)$7.38M
Total Debt (Recent Filing)$33.00K
Price to Earnings (P/E)―
Beta2.92
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-49.16
Shares Outstanding1,944,279
10 Day Avg. Volume100,775
30 Day Avg. Volume2,541,249
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.23
Price to Sales (P/S)0.00
P/FCF Ratio-0.23
Enterprise Value/Market Cap-4.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit164.19
Enterprise Value/Ebitda0.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA IDE SubmissionFiling an IDE to start a U.S. clinical trial represents a durable regulatory milestone that transitions the company from preclinical/feasibility work toward pivotal human data. If cleared, the trial can generate the clinical evidence required for future approvals and commercialization, materially de‑risking regulatory pathway over the next 2–6 months and strengthening strategic partner and payer engagement.
Peer‑reviewed Preclinical ValidationA published, long‑duration in‑vivo study demonstrating accuracy and safety provides independent scientific validation of the sensor platform. This durable evidence reduces technical risk, supports regulatory submissions, bolsters clinician confidence and differentiates the technology versus short‑life competitors, improving chances of adoption and partnership discussions over the medium term.
IP, Manufacturing And Management ReadinessAn expanding patent estate plus a dual‑source manufacturing strategy and industry‑experienced management form structural advantages. Patents protect core sensor chemistry and lead design, lowering competitive erosion; dual manufacturing reduces supply risk; seasoned leadership increases odds of navigating regulatory, reimbursement and commercialization steps reliably.
Bears Say
Pre‑revenue With Widening LossesThe company remains pre‑revenue with negative gross profit and materially widening net losses, indicating it has not yet commercialized its technology. Persistent operating deficits erode resources, reduce runway for development and force prioritization of programs; absent near‑term commercialization, this weakens long‑term financial resilience and execution capacity.
High Cash BurnSustained negative operating cash flow and roughly $15M negative free cash flow in the trailing twelve months create an ongoing funding requirement. High absolute burn relative to current resources increases dependency on external capital, can delay clinical timelines if financing is constrained, and raises execution risk for regulatory and commercialization activities.
Financing Pressure And Dilution RiskNegative shareholders' equity, repeated debt‑for‑equity exchanges and shareholder approvals to enable large equity issuances signal persistent financing pressure. Reliance on structured capital transactions increases dilution risk and may limit strategic flexibility, complicating long‑term investor returns and potentially constraining partner negotiations or commercial investments.
GlucoTrack News
GCTK FAQ
What was GlucoTrack’s price range in the past 12 months?
GlucoTrack lowest stock price was $0.62 and its highest was $15.90 in the past 12 months.
What is GlucoTrack’s market cap?
GlucoTrack’s market cap is $1.56M.
When is GlucoTrack’s upcoming earnings report date?
GlucoTrack’s upcoming earnings report date is May 20, 2026 which is in 10 days.
How were GlucoTrack’s earnings last quarter?
GlucoTrack released its earnings results on Mar 30, 2026. The company reported -$3.984 earnings per share for the quarter, missing the consensus estimate of N/A by -$3.984.
Is GlucoTrack overvalued?
According to Wall Street analysts GlucoTrack’s price is currently Overvalued.
Does GlucoTrack pay dividends?
GlucoTrack does not currently pay dividends.
What is GlucoTrack’s EPS estimate?
GlucoTrack’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GlucoTrack have?
GlucoTrack has 1,944,279 shares outstanding.
What happened to GlucoTrack’s price movement after its last earnings report?
GlucoTrack reported an EPS of -$3.984 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -14.021%.
Which hedge fund is a major shareholder of GlucoTrack?
Currently, no hedge funds are holding shares in GCTK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GlucoTrack
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.
Technical Analysis
Ownership Overview
0.58% Insiders
0.56% Mutual Funds
<0.01% Other Institutional Investors
98.86% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---